10 Billion Antidepressant Drug Market, 2022H1 Sales TOP5

Depression, a common mental disorder, is mainly manifested by symptoms such as low mood, decreased interest, slow thinking, poor diet and sleep, depression is also associated

According to the World Health Organization, there are more than 350 million people with depression worldwide in 2021, of which up to 54 million people in China have depression, accounting for 4.

As more and more patients seek help for treatment, it is estimated that by 2030, the overall market size of domestic antidepressants is expected to exceed 20 billion yuan

(Source: Minnet)

At present, the most commonly used first-line drugs for the treatment of depression are selective serotonin reuptake inhibitors (SSRIs), mainly citalopram, fluoxetine, paroxetine, sertraline and fluvoxamine, these five antidepressants are known as the "five golden flowers" by the industry; There are also novel antidepressants of the class of serotonin norepinephrine reuptake inhibitors (SNRIs), commonly known as dual-channel drugs, such as duloxidin and venlafaxine

SSRI and SNRI antidepressants have certain advantages over other antidepressants: it can be attributed to STEPS:S (Safety): small side effects, good safety; T (Tolerability): good tolerance, high safety; E (Efficacy): the efficacy is about 50%-70%; P (Payment): Single dose drugs are relatively expensive, and the total course cost is not more than that of traditional drugs such as tricyclic drugs; S(Simplicity): Easy to

Melatonin receptor agonists (MT1 and MT2 receptors) and 5-HT2C receptor antagonists agomelatine have emerged in recent years and occupy an increasingly high

Antidepressant drug TOP5

In the first half of 2022, the top 20 lists of domestic sample hospitals were: escitalopram, agomeratine, sertraline, venlafaxine and mirtazapine

Escitalopram

Escitalopram was originally researched as Lingbei, Denmark, which was approved by the FDA in 2002 to be listed in the United States, and entered the Chinese market in 2006, with the commodity name "Lespuer"

Judging from the terminal sales of sample hospitals in China, in addition to the impact of 4+7 collection and the new crown epidemic in 2019 and 2020, sales have declined, and in 2021, they have resumed a strong growth momentum, with annual sales revenue of 389 million yuan, an increase of 20.

From the perspective of market competition pattern, the four pharmaceutical companies of Lingbei Pharmaceutical, Kelun Pharmaceutical, Jingwei Pharmaceutical and Dongting Pharmaceutical basically cover the entire market

Agomelatine

Agomelatine is an antidepressant that combines melatonin MT1/MT2 receptor agonists and serotonin (5-HT2C) receptor antagonists, and is often used clinically to treat depression in adults and improve its accompanying symptoms

Agomelatine was originally a French Sveia, which was first approved for listing in the European Union in 2009 and listed in China in 2010

Agomelatine has been cutting thorns and climbing steadily in recent years, gradually surpassing large varieties of antidepressants such as sertraline, ranking fifth in the list of antidepressants in sample hospitals in 2020, entering the top three in 2021, and H1 has risen to second place

According to intranet data, in 2021, the sales of agomelatine domestic sample hospitals exceeded 200 million, up to 225 million yuan, up 61.

Sertraline

Sertraline was developed by Pfizer and listed after being approved by the FDA in 1991, and was approved to enter the Chinese market in 1998, with the trade name "Zolofo", and the patent protection period ended

The clinical advantage is that it is particularly suitable for women and the elderly and is safe for children and adolescents
.
In terms of the approved indications in China and the United States, its FDA-approved indications are more extensive than in China, which also shows that the quality of sertraline drugs is high and it is expected to continue to expand indications
in China.

Judging from the terminal data of China's sample hospitals, the sales of sertraline have expanded from 228 million yuan (2016) to 336 million yuan (2019)
year by year.
However, after the sertraline was included in the third batch of collection, sales fell rapidly, only about 200 million in 2021, H1 continued to decline in 2022, and the current sales did not exceed 100 million, only 89.
68 million yuan, down 10.
94%
year-on-year.

In terms of the competitive landscape, Pfizer, Jingxin Pharmaceutical and Huahai Pharmaceutical are divided into three enterprises to divide most of the domestic market
.
Among them, the market share of the original research Pfizer is gradually shrinking, and by 2022, H1 has shrunk to 56%.

As the first imitation enterprise of Sertraline dispersion film, Jingxin Pharmaceutical co.
, Ltd.
, its market share is expanding
year by year.

Venlafaxine

As a new generation of antidepressants, venlafaxine exerts an antidepressant effect by inhibiting the reuptake of serotonin and norepinephrine, and is suitable for concomitant anxiety-depressive disorders and generalized anxiety disorders
.
Developed by Wyeth (later acquired by Pfizer), Venlafaxine was approved by the FDA in December 1993 and first listed in the United States in April 1994 under the trade name "Innos"
.

Despite the sharp decline in sales in the international market after the expiration of the patent, venlafaxine still has a place
in antidepressants with its excellent efficacy.

In recent years, the average annual sales growth rate of public hospitals in key provinces and cities in China [Venlafaxine] has been stable, and sales have exceeded 300 million yuan
by 2021.
However, Wenlafaxine entered the fifth batch of collection last year, and sales plummeted in 2022, H1 was only 89.
68 million yuan, down 49.
23% year-on-year, and the ranking also slipped from the second to the fourth
last year.

Mirtazapine

Mirtazapine is the world's first antidepressant drug with a dual inhibitory effect on norepinephrine and serotonin, with a strong antidepressant effect; It recommends antidepressant drugs for the second edition of the Chinese Guidelines for the Prevention and Treatment of Depressive Disorders, the 2017 edition of the Chinese Medical Guidelines, the Practice Guidelines for the Treatment of Depression (The Third Edition), the American Psychiatric Association (APA) and other authoritative medical certifications
at home and abroad.

Rice nitrogen plain research is the Netherlands Organon (Oganon Pharmaceutical), which was first approved for listing in the Netherlands in 1994 and approved for domestic import in 2004
.

Mirtazapine is also a heavy variety of antidepressants with more than 100 million, and the growth rate is stable, ranking sixth in the list for many years since 2016, and this is the first time to enter the TOP5
.
According to the intranet, the sales data of public hospitals in key provinces and cities in H1 in 2022 is 68.
29 million yuan
.
The original research Ouganong accounted for nearly 40% (38.
53), followed by
Huayu Pharmaceutical (24.
86%), Harbin Sanlian (18.
99%), Shanxi Kangbao (15.
05%), etc.